Cyclooxygenase-2 (COX-2) overexpression is associated with a poor prognosis in non–
small-cell lung cancer (NSCLC) and may promote resistance to epidermal growth factor …

BACKGROUND: Apricoxib, a novel once‐daily selective cyclooxygenase‐2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …

Purpose Overexpression of COX-2 correlates with advanced stage and worse outcomes in
non–small-cell lung cancer (NSCLC), possibly as a result of elevated levels of COX-2 …

Abstract Purpose: Overexpression of cyclooxygenase-2 (COX-2) activates extracellular
signal-regulated kinase/mitogen-activated protein kinase signaling in an epidermal growth …

Abstract Aim: Inhibition of cyclooxygenase-2 (COX-2) is proposed as a treatment option in
several cancer types. However, in non-small cell lung cancer (NSCLC), phase III trials have …

Accumulating preclinical and clinical studies have shown that cyclooxygenase-2 (COX-2)
inhibitor has some efficacy for non-small cell lung cancer (NSCLC). However, two phase III …

Background The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy.
We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in …

Abstract Purpose: Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, potentiates antitumor
effects of erlotinib in preclinical studies, and COX-2 is frequently expressed in non–small cell …

BACKGROUND Cyclooxygenase 2 (COX‐2)‐dependent signaling represents a potential
mechanism of resistance to therapy with epidermal growth factor receptor (EGFR) tyrosine …

Purpose Tumor overexpression of cyclooxygenase-2 (COX-2) has been associated with
worse outcome in non–small-cell lung cancer (NSCLC). In Cancer and Leukemia Group B …